{
  "meta": {
    "title": "Cytotoxic_Drugs",
    "url": "https://brainandscalpel.vercel.app/cytotoxic-drugs-527abd07.html",
    "scrapedAt": "2025-11-29T18:33:31.837Z"
  },
  "questions": [
    {
      "id": 10904,
      "choices": [
        {
          "id": 43582,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute lymphoblastic leukemia (ALL) </span></span></span></p>"
        },
        {
          "id": 43583,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute Myeloblastic Leukemia (AML)</span></span></span></p>"
        },
        {
          "id": 43584,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocyctic leukemia (CLL)</span></span></span></p>"
        },
        {
          "id": 43585,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Myelocytic Leukemia (CML)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 7-year-old child is started on chemotherapy. One of the medications used in the treatment is L-asparaginase. This drug works by depleting asparagine, an amino acid that is required for the growth and survival of leukemia cells. Which of the following cancers is L-asparaginase commonly used to treat?</span></span></span></p>",
      "unique_key": "Q8118107",
      "question_audio": null,
      "question_video": null,
      "map_id": 36455,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute lymphoblastic leukemia (ALL)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase </strong>is an enzyme that is <strong>used in the treatment of acute lymphoblastic leukemia (ALL)</strong>. <strong>ALL</strong> is a cancer of the <strong>blood and bone marrow</strong> that affects <strong>white blood cells.</strong> The drug works by<strong> depleting the level of the amino acid</strong> <strong>asparagine</strong>, which is required for the<strong> growth and survival of leukemia cells.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Normal cells</strong> can <strong>synthesize asparagine</strong>, but <strong>leukemia cells</strong> are <strong>unable</strong> to do so and rely on an <strong>external source </strong>of <strong>asparagine for survival</strong>. <strong>L-asparaginase</strong> works by <strong>breaking down asparagine</strong> in the blood, thus <strong>depriving</strong> the <strong>leukemia</strong> <strong>cells of the amino acid</strong> that they need to<strong> survive.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase </strong>is typically used in <strong>combination with other chemotherapeutic agents</strong> in the treatment of<strong> ALL</strong>. While it is generally <strong>well tolerated,</strong> it can cause a<strong> few side effects,</strong> including <strong>hypersensitivity reactions</strong>, <strong>coagulation disorders</strong>, and <strong>liver dysfunction. </strong>In addition,<strong> L-asparaginase</strong> can also deplete other <strong>essential amino acids</strong>, which can <strong>lead </strong>to a range of <strong>adverse effects,</strong> including <strong>pancreatitis, hyperglycaemia, and neurological complications.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute Myeloblastic Leukemia (AML):</span></strong><span style=\"font-size:12.0pt\"> AML is another <strong>type of leukemia</strong> but primarily affects <strong>different lineages of cells</strong> within the<strong> bone marrow</strong>.<strong> L-asparaginase</strong> is <strong>not</strong> typically<strong> used</strong> in the treatment of<strong> AML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chronic lymphocytic leukemia (CLL):</span></strong><span style=\"font-size:12.0pt\"> CLL <strong>progresses</strong> <strong>more slowly than ALL </strong>and generally affects<strong> older adults.</strong> It is <strong>not</strong> treated with<strong> L-asparaginase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic Myelocytic Leukemia (CML):</span></strong><span style=\"font-size:12.0pt\"> CML is a<strong> chronic form of leukemia </strong>affecting primarily <strong>adults</strong>.<strong> L-asparaginase</strong> is <strong>not</strong> effective<strong> against CML cells</strong> as they<strong> do not</strong> rely on<strong> external sources of asparagine</strong> like<strong> ALL cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase</strong> is particularly significant in the <strong>treatment of acute lymphoblastic leukemia (ALL) </strong>due to its unique mechanism of <strong>depleting asparagine</strong>, which is <strong>essential for the survival of ALL cells</strong>. This makes it a <strong>key component</strong> of <strong>chemotherapy regimens</strong> for <strong>ALL,</strong> especially in<strong> pediatric patients</strong>, where it can be <strong>combined with other drugs</strong> to enhance <strong>treatment efficacy and </strong>manage the <strong>disease effectively.</strong></span></span></span></p>",
      "correct_choice_id": 43582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10897,
      "choices": [
        {
          "id": 43554,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine</span></span></span></p>"
        },
        {
          "id": 43555,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
        },
        {
          "id": 43556,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mithramycin</span></span></span></p>"
        },
        {
          "id": 43557,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adriamycin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old male presents with a cough, shortness of breath, and chest pain. Imaging studies reveal a mass in the lung, and a biopsy confirms the diagnosis of carcinoma lung. The patient has a history of chronic obstructive pulmonary disease (COPD) and bronchiectasis. He is currently on bronchodilators, inhaled corticosteroids, and oxygen therapy. The oncologist recommends chemotherapy for the treatment of the cancer. Which of the following drugs should be avoided in this patient?</span></span></span></p>",
      "unique_key": "Q5725673",
      "question_audio": null,
      "question_video": null,
      "map_id": 36451,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong>, an<strong> antineoplastic agent, </strong>is <strong>widely used </strong>to treat <strong>lung cancer, lymphomas, and other cancers.</strong> Its significant<strong> side effect</strong> of <strong>pulmonary toxicity,</strong> which may present as<strong> interstitial pneumonitis or pulmonary fibrosis, </strong>is particularly<strong> dangerous </strong>in patients with <strong>pre-existing lung </strong>conditions such as<strong> COPD and bronchiectasis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Given the patient&#39;s<strong> respiratory history and ongoing lung challenges</strong>, the <strong>risk </strong>of<strong> exacerbating pulmonary symptoms</strong> or inducing further <strong>lung damage</strong> makes <strong>Bleomycin a poor choice.</strong> This<strong> heightened sensitivity</strong> to<strong> lung-related side effects</strong> necessitates the <strong>avoidance of Bleomycin</strong> in favor of other <strong>chemotherapeutic agents</strong> <strong>less likely </strong>to affect <strong>pulmonary function.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vinblastine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While Vinblastine can have its own set of <strong>side effect</strong>s, including<strong> bone marrow suppression</strong> and <strong>neurotoxicity</strong>, it <strong>does not </strong>specifically <strong>exacerbate lung </strong></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>conditions</strong> like <strong>COPD or bronchiectasis,</strong> making it a<strong> safer</strong> option than Bleomycin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mithramycin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This drug is used in the treatment of <strong>testicular cancer </strong>and<strong> certain types</strong> of<strong> hypercalcemia</strong> but is<strong> less</strong> commonly associated with <strong>pulmonary complications,</strong> making it a potentially <strong>safer option </strong>for this patient.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adriamycin (Doxorubicin):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Adriamycin is known for its <strong>cardiotoxicity rather than pulmonary toxicity,</strong> and therefore, it <strong>does not pose</strong> the same specific <strong>risk to patients with pre-existing lung diseases as Bleomycin</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with<strong> pre-existing lung </strong>conditions such as <strong>COPD and bronchiectasis, Bleomycin</strong> should be<strong> avoided </strong>due to its<strong> potential to</strong> cause significant <strong>pulmonary toxicity.</strong></span></span></span></p>",
      "correct_choice_id": 43555,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10933,
      "choices": [
        {
          "id": 43698,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Actinomycin</span></p>"
        },
        {
          "id": 43699,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Doxorubicin</span></p>"
        },
        {
          "id": 43700,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Bleomycin</span></p>"
        },
        {
          "id": 43701,
          "text": "<p><span style=\"font-size:18px;\">Mitomycin C</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">After 15 days of chemotherapy, a patient develops rash and itching on the back as shown in the image. It can occur as a side effect of which of the following drugs?&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/415.jpg\" alt=\"\" width=\"250\" height=\"348\"></span></p>",
      "unique_key": "Q3499495",
      "question_audio": null,
      "question_video": null,
      "map_id": 36471,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Ans. C) Bleomycin</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Bleomycin</strong> is a<strong> chemotherapeutic agent</strong> that is known to cause a <strong>distinctive pattern of skin pigmentation</strong> called <strong>\"flagellate pigmentation\".</strong> This pattern is characterized by <strong>linear streaks of hyperpigmentation </strong>that resemble the<strong> tracks left by a whip, </strong>or <strong>flagellum.</strong> This reaction is<strong> more</strong> commonly seen in<strong> women</strong> and can <strong>occur several weeks to months</strong> after <strong>starting therapy. </strong>The pigmentation <strong>usually resolves spontaneously</strong>,<strong> but</strong> in some cases, it <strong>can persist for several months to years </strong>after <strong>stopping the</strong> <strong>medication.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option A. Actinomycin:&nbsp;</strong>While actinomycin can cause <strong>side effects</strong> including <strong>nausea and myelosuppression,</strong> it is <strong>not</strong> typically associated with <strong>flagellate pigmentation.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option B. Doxorubicin:&nbsp;</strong>Doxorubicin's <strong>side effect</strong> profile includes<strong> cardiotoxicity and myelosuppression</strong>; <strong>flagellate pigmentation</strong> is<strong> not</strong> a common reaction with <strong>this drug.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option D. Mitomycin C:&nbsp;</strong>This <strong>chemotherapeutic agent </strong>is more commonly associated with <strong>bone marrow suppression and renal</strong> <strong>toxicity, not</strong> the distinctive<strong> skin pigmentation</strong> seen with <strong>Bleomycin.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Flagellate pigmentation</strong> is a <strong>distinctive cutaneous side effect</strong> associated with <strong>Bleomycin therapy.</strong></span></p>",
      "correct_choice_id": 43700,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/10933/FMGE_20_Sep_2025_PHARMACOLOGY_Question_13.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/10933/FMGE_20_Sep_2025_PHARMACOLOGY_Question_13.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10903,
      "choices": [
        {
          "id": 43578,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitoxantrone </span></span></span></p>"
        },
        {
          "id": 43579,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan</span></span></span></p>"
        },
        {
          "id": 43580,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel </span></span></span></p>"
        },
        {
          "id": 43581,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following drugs acts specifically on the M phase of the cell cycle?</span></span></span></p>",
      "unique_key": "Q2317996",
      "question_audio": null,
      "question_video": null,
      "map_id": 36454,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paclitaxel</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Paclitaxel </strong>is a <strong>chemotherapy agent</strong> that falls under the<strong> category of taxanes,</strong> which are known for their ability to<strong> inhibit the</strong> <strong>depolymerization of tubulin</strong>. <strong>Tubulin </strong>is a key<strong> protein</strong> involved in <strong>spindle formation</strong> during the<strong> M phase of the cell cycle.</strong> By <strong>stabilizing tubulin polymers,</strong> <strong>paclitaxel effectively </strong>prevents the<strong> spindle fibers from breaking down,</strong> which is essential for<strong> cell</strong> <strong>division.</strong> This <strong>inhibition locks the cells </strong>in the<strong> M phase</strong>, <strong>preventing </strong>them from <strong>successfully completing mitosis</strong>, thus<strong> inhibiting cell</strong> <strong>division and proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mitoxantrone:</span></strong><span style=\"font-size:12.0pt\"> This drug is a <strong>type of antitumor antibiotic </strong>that interferes with<strong> DNA replication and RNA synthesis</strong> but <strong>does</strong> <strong>not </strong>specifically act on the<strong> M phase</strong>. It is classified among<strong> topoisomerase inhibitors</strong> and is used primarily for <strong>its action</strong> in various <strong>phases of the cell cycle,</strong> but <strong>not </strong>specifically the <strong>M phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Topotecan:</span></strong><span style=\"font-size:12.0pt\"> As a<strong> topoisomerase inhibitor, </strong>Topotecan <strong>interferes</strong> with the <strong>ability of topoisomerases</strong> to <strong>relieve torsional</strong> <strong>strain on DNA during replication </strong>and<strong> transcription</strong>. It is <strong>primarily active</strong> in the<strong> S phase of the cell cycle</strong>, not the M phase.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> Another antitumor antibiotic,<strong> Daunorubicin</strong> is involved in <strong>intercalating DNA</strong> and<strong> inhibiting the enzyme</strong> <strong>topoisomerase II,</strong> which <strong>prevents the relaxation of supercoiled DNA and promotes DNA breakage </strong>during <strong>replication</strong>. Like <strong>Mitoxantrone</strong>, it <strong>does not</strong> specifically <strong>target the M phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-121414.png\" style=\"height:454px; width:1000px\" /></span></u></strong></span></span></p>",
      "correct_choice_id": 43580,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10895,
      "choices": [
        {
          "id": 43546,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines </span></span></span></p>"
        },
        {
          "id": 43547,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alkylating agents </span></span></span></p>"
        },
        {
          "id": 43548,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum compounds </span></span></span></p>"
        },
        {
          "id": 43549,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bisphosphonates</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman named Hema has locally advanced breast cancer and has been recommended for chemotherapy. She has a history of myocardial infarction and congestive heart failure. Which antineoplastic drug should be avoided in her treatment?</span></span></span></p>",
      "unique_key": "Q3692302",
      "question_audio": null,
      "question_video": null,
      "map_id": 36450,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Anthracyclines</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Anthracyclines,</strong> such as <strong>doxorubicin, daunorubicin, idarubicin, and epirubicin,</strong> are commonly used in the treatment of<strong> breast cancer.</strong> However, they should be <strong>avoided in Hema&#39;s case</strong> due to their <strong>known association with cardiotoxicity,</strong> which can be especially <strong>hazardous for patients</strong> with <strong>existing heart conditions</strong> like <strong>myocardial infarction</strong> and <strong>congestive heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Anthracyclines</strong> can exacerbate these conditions by <strong>causing left ventricular dysfunction, arrhythmias, and heart failure.</strong> The <strong>cardiotoxicity from anthracyclines </strong>is primarily due to the generation of <strong>iron-mediated free radicals</strong>. <strong>Dexrazoxane</strong> is sometimes used as a <strong>free radical scavenger </strong>to <strong>prevent this cardiotoxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alkylating agents:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> because while<strong> alkylating agents </strong>are used in<strong> breast cancer treatment</strong>, they are <strong>not </strong>specifically associated with <strong>increased risk of cardiotoxicity, </strong>which is<strong> Hema&#39;s primary</strong> concern given her<strong> cardiac history.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Platinum compounds:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>as <strong>platinum compounds, </strong>commonly used in <strong>various cancers </strong>including <strong>breast cancer,</strong> do <strong>not</strong> have a <strong>direct link to cardiotoxicity</strong> that would particularly <strong>exacerbate Hema&rsquo;s existing heart conditions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bisphosphonates:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> because <strong>bisphosphonates </strong>are <strong>not</strong> primarily<strong> antineoplastic drugs</strong> but are used to manage <strong>bone metastases </strong>and <strong>prevent bone loss in cancer patients</strong> undergoing<strong> hormonal therapy. </strong>They <strong>do not</strong> pose a <strong>risk of cardiotoxicity,</strong> though they have <strong>other side effects </strong>like <strong>renal dysfunction and osteonecrosis of the jaw.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For a patient with a <strong>history of heart disease</strong>, it is crucial to<strong> avoid anthracyclines </strong>due to their potential to <strong>cause severe cardiotoxicity.</strong> <strong>Alternative chemotherapy </strong>agents <strong>should be </strong>considered that <strong>do not exacerbate heart conditions.</strong></span></span></span></p>",
      "correct_choice_id": 43546,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10894,
      "choices": [
        {
          "id": 43542,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folinic acid enhances the action of methotrexate</span></span></span></p>"
        },
        {
          "id": 43543,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate acts by inhibiting dihydrofolate reductase</span></span></span></p>"
        },
        {
          "id": 43544,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-proliferative cells are relatively resistant to methotrexate</span></span></span></p>"
        },
        {
          "id": 43545,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate can be used in the treatment of psoriasis</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following statements about methotrexate are correct except:</span></span></span></p>",
      "unique_key": "Q2972366",
      "question_audio": null,
      "question_video": null,
      "map_id": 36449,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Folinic acid enhances the action of methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The statement is<strong> incorrect </strong>because<strong> folinic acid (leucovorin)</strong> is actually used to <strong>mitigate the toxic effects of methotrexate</strong>, particularly when<strong> administered in high doses. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Folinic acid</strong> provides a means of &quot;<strong>rescue&quot;</strong> by supplementing the body with a <strong>form of folate</strong> that<strong> does not </strong>require activation by <strong>dihydrofolate reductase (DHFRase)</strong>, thus allowing for <strong>normal cellular functions </strong>to continue despite<strong> methotrexate&#39;s inhibition</strong> of the enzyme.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate acts by inhibiting dihydrofolate reductase:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>correct</strong>. Methotrexate is an<strong> anti-metabolite</strong> that <strong>inhibits DHFRase, reducing</strong> the formation of<strong> tetrahydrofolate </strong>required for<strong> purine and thymidylate synthesis</strong>, which are essential for<strong> DNA replication and cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Non-proliferative cells are relatively resistant to methotrexate:</span></strong><span style=\"font-size:12.0pt\"> This is <strong>correct.</strong> Methotrexate&#39;s mechanism targets the<strong> S-phase of the cell cycle, </strong>affecting <strong>rapidly dividing cells;</strong> thus, cells that are in a <strong>resting state show relative resistance.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Methotrexate can be used in the treatment of psoriasis:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true</strong>. Beyond its oncological applications, methotrexate is used as a<strong> first-line disease-modifying anti-rheumatic drug (DMARD) </strong>and is <strong>effective</strong> for conditions like<strong> psoriasis and</strong> <strong>ectopic pregnancy</strong> due to its <strong>anti-proliferative effects </strong>on <strong>fast-dividing cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate </strong>is a <strong>critical drug</strong> used for a variety of conditions, including as the <strong>drug of choice for choriocarcinoma</strong> and a <strong>first-line</strong> <strong>DMARD</strong>. It is <strong>essential</strong> to understand that while<strong> methotrexate inhibits DHFRase,</strong> leading to<strong> decreased DNA synthesis </strong>in <strong>proliferating cells, folinic acid </strong>is used to<strong> rescue normal cells </strong>from its<strong> toxic effects, not</strong> enhance its <strong>action.</strong></span></span></span></p>",
      "correct_choice_id": 43542,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10912,
      "choices": [
        {
          "id": 43614,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cladribine</span></span></span></p>"
        },
        {
          "id": 43615,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine</span></span></span></p>"
        },
        {
          "id": 43616,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Capecitabine</span></span></span></p>"
        },
        {
          "id": 43617,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients undergoing treatment for colorectal cancer have developed symptoms such as tingling, numbness, pain, and erythema on the palms and soles of their feet as shown in the figure below. Which of the following chemotherapy drugs could be the causative agent?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/403_RU0SYwK.jpg\" style=\"height:280px; width:500px\" /></span></span></span></p>",
      "unique_key": "Q9876037",
      "question_audio": null,
      "question_video": null,
      "map_id": 36457,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Capecitabine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms described &ndash; <strong>tingling, numbness, pain, and erythema</strong> on the <strong>palms and soles </strong>&ndash; are<strong> indicative </strong>of a condition <strong>known as</strong> <strong>hand-foot syndrome</strong> or <strong>palmar-plantar erythrodysesthesia</strong>. This condition is a <strong>known side effect </strong>of certain <strong>chemotherapy drugs</strong>. Among the options given, the <strong>drug</strong> most likely to <strong>cause</strong> these symptoms in patients<strong> undergoing treatment for colorectal cancer</strong> is <strong>capecitabine</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Capecitabine</strong> is an <strong>oral prodrug of 5-fluorouracil (5-FU)</strong> and is commonly used in the treatment of <strong>colorectal cancer.</strong> <strong>Hand-foot</strong> <strong>syndrome </strong>is a <strong>well-known </strong>and <strong>relatively common</strong> side effect of <strong>capecitabine,</strong> characterized by <strong>redness, swelling, pain, </strong>and <strong>numbness</strong> in the <strong>palms of the hands and soles of the feet.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cladribine</strong>: Primarily<strong> used</strong> in<strong> hairy cell leukemia,</strong> <strong>cladribine</strong> can cause <strong>several side effects</strong> but is <strong>not </strong>typically associated with<strong> hand-foot syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Gemcitabine</strong>: Used in<strong> various cancers</strong>, including <strong>pancreatic, breast, and non-small cell lung cancer</strong>. While <strong>gemcitabine </strong>has many<strong> side effects,</strong> it is<strong> less</strong> commonly associated with<strong> hand-foot syndrome</strong> compared to<strong> capecitabine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Bleomycin</strong>: Used in the <strong>treatment of Hodgkin&#39;s lymphoma</strong>, <strong>testicular cancer,</strong> and<strong> other types of cancer. Bleomycin</strong> is <strong>more </strong>known for<strong> pulmonary side effects,</strong> and<strong> hand-foot syndrome</strong> is<strong> not</strong> a <strong>typical side effect of this drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Capecitabine</strong> is the likely cause of the symptoms due to its <strong>known </strong>association with<strong> hand-foot syndrome</strong>, particularly in patients treated for<strong> colorectal cancer.</strong></span></span></span></p>",
      "correct_choice_id": 43616,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10893,
      "choices": [
        {
          "id": 43538,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is metabolized by cytochrome p450 enzymes</span></span></span></p>"
        },
        {
          "id": 43539,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is less neurotoxic than cyclophosphamide</span></span></span></p>"
        },
        {
          "id": 43540,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chloroacetaldehyde is the metabolite of ifosfamide</span></span></span></p>"
        },
        {
          "id": 43541,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is an alkylating agent</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following statements are true regarding ifosfamide except?</span></span></span></p>",
      "unique_key": "Q4625536",
      "question_audio": null,
      "question_video": null,
      "map_id": 36448,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Less neurotoxic than cyclophosphamide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>correct</strong> statement that is <strong>false</strong> about <strong>ifosfamide</strong> is that it is <strong>less neurotoxic than cyclophosphamide.</strong> In fact,<strong> ifosfamide</strong> is associated with<strong> greater neurotoxicity</strong> compared <strong>to cyclophosphamide.</strong> This is a critical consideration in clinical settings, as <strong>ifosfamide&#39;s neurotoxic effects</strong> can<strong> limit its dosage </strong>and r<strong>equire careful monitoring.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is metabolized by cytochrome p450 enzymes:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true.</strong> <strong>Ifosfamide</strong>, like many other <strong>alkylating agents</strong> including <strong>cyclophosphamide</strong>, is metabolized by<strong> cytochrome p450 enzymes, </strong>which play a key role in its<strong> activation and detoxification.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chloroacetaldehyde is the metabolite of ifosfamide:</span></strong><span style=\"font-size:12.0pt\"> This is also<strong> true</strong>. The metabolism of<strong> ifosfamide</strong> involves the <strong>production of chloroacetaldehyde</strong>, a <strong>metabolite</strong> that contributes to<strong> its nephrotoxic effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It is an alkylating agent:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>correct</strong>. <strong>Ifosfamide</strong> belongs to the <strong>nitrogen mustard group of alkylating agents,</strong> which are used in <strong>cancer chemotherapy</strong> to <strong>alkylate the DNA of cancer cells</strong>, leading to <strong>cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ifosfamide, </strong>while being a valuable <strong>chemotherapeutic alkylating agent</strong>, carries a significant <strong>risk of neurotoxicity</strong> that is <strong>greater than</strong> that of <strong>cyclophosphamide. </strong>This fact must be <strong>carefully considered </strong>when <strong>prescribing and managing treatment with ifosfamide </strong>in clinical practice.</span></span></span></p>",
      "correct_choice_id": 43539,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10898,
      "choices": [
        {
          "id": 43558,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil</span></span></span></p>"
        },
        {
          "id": 43559,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
        },
        {
          "id": 43560,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
        },
        {
          "id": 43561,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common side effect of cancer chemotherapy is nausea with or without vomiting. The anticancer drugs vary is their ability to cause nausea and vomiting. Which of the following anti-cancer drugs is least likely to cause nausea and vomiting?</span></span></span></p>",
      "unique_key": "Q8766742",
      "question_audio": null,
      "question_video": null,
      "map_id": 36452,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Chlorambucil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong> is an<strong> alkylating agent</strong> typically used in the treatment of <strong>chronic lymphocytic leukemia</strong> and other <strong>hematological</strong> <strong>malignancies.</strong> Compared to the other drugs listed, <strong>chlorambucil</strong> has a<strong> lower emetogenic potential</strong>, meaning it is <strong>less likely</strong> to cause <strong>nausea and vomiting.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cisplatin and cyclophosphamide </strong>have v<strong>ery high emetogenic potential </strong>whereas <strong>chlorambucil and busulfan</strong> have the <strong>least. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> Known for its<strong> high emetogenic potential,</strong> cisplatin is a <strong>platinum-based drug </strong>that often requires <strong>premedication</strong> <strong>with antiemetics </strong>to manage its <strong>severe nausea and vomiting</strong> side effects.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Doxorubicin:</span></strong><span style=\"font-size:12.0pt\"> As an<strong> anthracycline, doxorubicin</strong> has a <strong>moderate to high emetogenic potential</strong>, necessitating the <strong>use of</strong> <strong>antiemetics</strong> for patient <strong>comfort during treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> <strong>Similar</strong> in class to <strong>doxorubicin</strong>, <strong>daunorubicin</strong> also has a<strong> moderate to high emetogenic risk, </strong>which can affect patient<strong> quality of life and treatment adherence.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When considering the <strong>side effect </strong>profile of <strong>chemotherapeutic agents,</strong> especially regarding <strong>emesis,</strong> <strong>chlorambucil </strong>is noted for its <strong>lower likelihood </strong>of causing <strong>nausea and vomiting </strong>relative to other agents like <strong>cisplatin, doxorubicin, and daunorubicin. </strong></span></span></span></p>",
      "correct_choice_id": 43558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10899,
      "choices": [
        {
          "id": 43562,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folinic acid and vitamin B6</span></span></span></p>"
        },
        {
          "id": 43563,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folic acid and vitamin B12</span></span></span></p>"
        },
        {
          "id": 43564,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B6 and vitamin B12</span></span></span></p>"
        },
        {
          "id": 43565,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folic acid and dexamethasone</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following medications is essential for ameliorating the toxicity of pemetrexed?</span></span></span></p>",
      "unique_key": "Q7815960",
      "question_audio": null,
      "question_video": null,
      "map_id": 36453,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Folic acid and vitamin B12</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pemetrexed </strong>is a <strong>chemotherapy agent </strong>primarily used to <strong>treat lung cancer and mesothelioma.</strong> A <strong>major side effect</strong> of pemetrexed is <strong>myelosuppression</strong>, which can lead to serious<strong> blood-related issues </strong>such as <strong>anemia, neutropenia, and thrombocytopenia.</strong> To <strong>counteract this toxicity</strong>, supplementation with<strong> folic acid and vitamin B12 </strong>is recommended. <strong>Folic acid </strong>helps maintain necessary levels of <strong>folate within cells</strong>, aiding in<strong> DNA and RNA synthesis </strong>which are crucial <strong>during cell division. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pemetrexed interferes</strong> with<strong> folate metabolism by inhibiting</strong> key <strong>enzymes</strong>; therefore, <strong>folic acid supplementation</strong> is vital to <strong>mitigate</strong> this effect. Similarly,<strong> vitamin B12 plays a critical role in DNA synthesis </strong>and <strong>red blood cell maturation. Supplementation with vitamin</strong> <strong>B12 </strong>helps <strong>prevent deficiencies</strong> that can <strong>exacerbate anemia </strong>and other <strong>hematological issues</strong> caused by <strong>pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Folinic acid and vitamin B6:</span></strong><span style=\"font-size:12.0pt\"> This combination is<strong> incorrect as folinic acid,</strong> while related to folate, is <strong>not </strong>used to mitigate the toxicity associated with pemetrexed, and <strong>vitamin B6 does not</strong> play a role in <strong>mitigating pemetrexed&#39;s specific toxic effects</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vitamin B6 and vitamin B12:</span></strong><span style=\"font-size:12.0pt\"> Vitamin B12 is <strong>correct</strong> in part; however,<strong> vitamin B6</strong> <strong>does not</strong> aid in <strong>ameliorating </strong>the <strong>specific</strong> <strong>toxicities of pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Folic acid and dexamethasone:</span></strong><span style=\"font-size:12.0pt\"> While<strong> folic acid </strong>is a <strong>correct component</strong>,<strong> dexamethasone </strong>is primarily used for its <strong>anti-inflammatory properties </strong>and <strong>not for</strong> <strong>mitigating myelosuppression</strong> caused by<strong> pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For<strong> patients</strong> undergoing<strong> treatment with pemetrexed</strong>, it is <strong>crucial to supplement</strong> with <strong>folic acid and vitamin B12</strong> to <strong>reduce the risk of</strong> <strong>myelosuppression </strong>and related <strong>complications. </strong>This supplementation strategy helps <strong>maintain necessary folate and vitamin B12</strong> <strong>levels</strong>, <strong>supporting DNA synthesis and red blood cell maturation</strong>, thereby<strong> counteracting the drug&#39;s </strong>potential <strong>hematological toxicities.</strong></span></span></span></p>",
      "correct_choice_id": 43563,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10906,
      "choices": [
        {
          "id": 43590,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil</span></span></span></p>"
        },
        {
          "id": 43591,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
        },
        {
          "id": 43592,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine</span></span></span></p>"
        },
        {
          "id": 43593,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old patient with non-Hodgkin&#39;s lymphoma is undergoing chemotherapy. The oncologist discusses the mechanism of action of various chemotherapeutic agents to optimize the patient&#39;s treatment regimen. Understanding the specific phases of the cell cycle that these drugs target is crucial for effective therapy.&nbsp;Which of the following chemotherapeutic agents acts predominantly during the S phase of the cell cycle?</span></span></span></p>",
      "unique_key": "Q9245504",
      "question_audio": null,
      "question_video": null,
      "map_id": 36456,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is a <strong>chemotherapeutic agent </strong>that acts as a<strong> folate analog to inhibit the enzyme dihydrofolate reductase. </strong>This enzyme is<strong> essential for the synthesis of tetrahydrofolate,</strong> a molecule necessary for the<strong> production of thymidine and purine nucleotides,</strong> which are <strong>required for DNA synthesis.</strong> Since DNA synthesis is a critical activity during the<strong> S phase of the cell cycle,</strong> <strong>methotrexate</strong> primarily exerts its<strong> cytotoxic effects in this phase</strong>, making it particularly <strong>effective against rapidly dividing cells</strong> such as those found in <strong>various cancers.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong>: This is an<strong> </strong><strong>alkylating agent</strong> that <strong>acts</strong> primarily in the <strong>G1 and S phases,</strong> but it&#39;s <strong>not as specific </strong>to the<strong> S phase</strong> compared to<strong> some other drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Vincristine</strong>: Vincristine is a<strong> mitotic inhibitor </strong>that primarily <strong>acts</strong> on the <strong>M phase of the cell cycle</strong>. It <strong>inhibits microtubule</strong> <strong>formation, </strong>which is <strong>crucial for cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Paclitaxel</strong>: Paclitaxel is also a<strong> mitotic inhibitor </strong>that <strong>acts </strong>mainly on the<strong> M phase.</strong> It<strong> stabilizes microtubules,</strong> <strong>preventing </strong>their <strong>disassembly,</strong> which is necessary for <strong>cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate&#39;s</strong> specific action of<strong> inhibiting DNA synthesis </strong>during the <strong>S phase.</strong></span></span></span></p>",
      "correct_choice_id": 43591,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 43254,
      "choices": [
        {
          "id": 172683,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil </span></span></span></p>"
        },
        {
          "id": 172684,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 172685,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine </span></span></span></p>"
        },
        {
          "id": 172686,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman with breast cancer is undergoing chemotherapy. She is currently receiving a drug that acts on the &#39;S&#39; phase of the cell cycle. Which of the following drugs is most likely being used in her treatment?</span></span></span></p>",
      "unique_key": "Q9224287",
      "question_audio": null,
      "question_video": null,
      "map_id": 36475,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate </strong>is a well-known <strong>chemotherapeutic agent</strong> that specifically targets the<strong> S phase of the cell cycle</strong>, which is the phase in which<strong> DNA synthesis occurs.</strong> It acts by<strong> inhibiting dihydrofolate reductase,</strong> an enzyme critical for the<strong> synthesis of tetrahydrofolate,</strong> necessary for the <strong>production of thymidylate and purine nucleotides</strong>&mdash;both <strong>essential </strong>components for <strong>DNA replication</strong> and <strong>cell</strong> <strong>division</strong>. This specific mechanism makes<strong> Methotrexate</strong> particularly <strong>effective during the S phase,</strong> where it can <strong>inhibit the growth of</strong> <strong>cancer cells </strong>by preventing<strong> DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chlorambucil:</span></strong><span style=\"font-size:12.0pt\"> This drug is an <strong>alkylating agent</strong> that is<strong> not </strong>specific to any<strong> particular phase of the cell cycle</strong>. It can form <strong>cross-links in DNA</strong> <strong>at any phase</strong>, thereby causing <strong>damage</strong> that leads to<strong> cell death.</strong> While effective <strong>against various cancers, </strong>it <strong>does</strong> <strong>not</strong> specifically target the<strong> S phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a<strong> vinca alkaloid</strong> that acts predominantly during the <strong>M phase of the cell cycle. </strong>It<strong> inhibits</strong> <strong>microtubule formation</strong>, which is essential for <strong>mitotic spindle</strong> assembly and <strong>chromosome</strong> separation during <strong>mitosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Paclitaxel:</span></strong><span style=\"font-size:12.0pt\"> Also acting in the<strong> M phase,</strong> Paclitaxel stabilizes <strong>microtubules </strong>and <strong>prevents </strong>their <strong>disassembly, </strong>thus<strong> inhibiting</strong> the <strong>completion of mitosis </strong>and <strong>leading to cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is a<strong> cell cycle-specific anticancer drug </strong>that acts by <strong>inhibiting DNA synthesis</strong> in the<strong> &#39;S&#39; phase</strong> of the cell cycle. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong> is a <strong>cell cycle-nonspecific alkylating agent </strong>that can affect cells in <strong>any phase of the cell cycle. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine and Paclitaxel </strong>are<strong> cell cycle-specific anticancer drug </strong>that acts in the<strong> &#39;M&#39; phase of the cell cycle.</strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 172684,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10913,
      "choices": [
        {
          "id": 43618,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is 5-Fluorourcail, and Y is Methotrexate</span></span></span></p>"
        },
        {
          "id": 43619,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is Methotrexate and Y is 5-Fluorouracil</span></span></span></p>"
        },
        {
          "id": 43620,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is Vincristine and Y is Methotrexate</span></span></span></p>"
        },
        {
          "id": 43621,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both X and Y are methotrexate</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mechanism of action of two anticancer drugs X and Y is shown in the figure below. Which of following statements most correctly represent drug X and Y?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/404.jpg\" style=\"height:505px; width:500px\" /></span></span></span></p>",
      "unique_key": "Q8710912",
      "question_audio": null,
      "question_video": null,
      "map_id": 36458,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) X is Methotrexate and Y is 5-Fluorouracil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> <strong>inhibits</strong> <strong>dihydrofolate reductase (DHFRase),</strong> an <strong>enzyme</strong> that is involved in the <strong>synthesis of nucleotides</strong>. By <strong>inhibiting DHFRase</strong>, methotrexate<strong> prevents the formation of tetrahydrofolate</strong>, which is required for the <strong>synthesis of</strong> <strong>thymidylate, purines, and other nucleotides.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>5-Fluorouracil (5-FU)</strong>, on the other hand, <strong>inhibits thymidylate synthase</strong>, an enzyme that is required for the <strong>synthesis of</strong> <strong>thymidylate</strong>, which is essential for <strong>DNA replication. </strong>By <strong>inhibiting thymidylate synthase,</strong> <strong>5-FU reduces </strong>the production of <strong>thymidylate </strong>and thereby <strong>inhibits DNA synthesis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. X is 5-Fluorouracil, and Y is Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> This is<strong> incorrect </strong>because <strong>5-FU does not inhibit DHFR </strong>but <strong>inhibits thymidylate</strong> <strong>synthase,</strong> and <strong>Methotrexate inhibits DHFR</strong>, <strong>not thymidylate synthase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>X is Vincristine and Y is Methotrexate: Vincristine</strong> is a <strong>microtubule inhibitor</strong> that<strong> blocks cell division </strong>by <strong>inhibiting the</strong> formation of the <strong>mitotic spindle</strong>. It<strong> does not</strong> <strong>inhibit</strong> thymidylate<strong> synthase or DHFRase.</strong> Therefore, <strong>option C is incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Both X and Y are methotrexate:</span></strong><span style=\"font-size:12.0pt\"> is also<strong> incorrect</strong> because <strong>both X and Y cannot be methotrexate,</strong> as they have <strong>different</strong> <strong>targets of action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate (Drug X) inhibits</strong> the enzyme<strong> DHFR,</strong> essential for<strong> DNA nucleotide synthesis,</strong> while<strong> 5-Fluorouracil (Drug Y) inhibits</strong> <strong>thymidylate synthase,</strong> critical for the <strong>production of the thymidine nucleotide</strong> necessary for<strong> DNA synthesis. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding these targets is key to <strong>recognizing</strong> the rationale behind using<strong> these drugs </strong>in the treatment of <strong>cancers like leukemia</strong> and<strong> colorectal cancer, respectively.</strong></span></span></span></p>",
      "correct_choice_id": 43619,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10915,
      "choices": [
        {
          "id": 43626,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of microtubule polymerization </span></span></span></p>"
        },
        {
          "id": 43627,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of DNA synthesis </span></span></span></p>"
        },
        {
          "id": 43628,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of DNA topoisomerase II </span></span></span></p>"
        },
        {
          "id": 43629,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of tyrosine kinase activity</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman presents with a diagnosis of non-Hodgkin&#39;s lymphoma. She is started on chemotherapy, which includes a drug derived from the periwinkle plant (Image shown below). Which of the following is the mechanism of action of this drug?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/406.jpg\" style=\"height:239px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q8659474",
      "question_audio": null,
      "question_video": null,
      "map_id": 36459,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Inhibition of microtubule polymerization</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> drugs derived</strong> <strong>from</strong> the <strong>periwinkle plant </strong>are <strong>vincristine and vinblastine.</strong> These belongs to the <strong>class of drugs</strong> known as <strong>vinca</strong> <strong>alkaloids</strong>. These act by<strong> inhibiting microtubule polymerization</strong>, which <strong>disrupts the formation of the mitotic spindle</strong> during<strong> cell</strong> <strong>division,</strong> leading to<strong> cell cycle arrest and apoptosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Doxorubicin and etoposide </strong>work by <strong>inhibiting DNA synthesis</strong> and <strong>DNA topoisomerase II,</strong> respectively, they are <strong>not</strong> <strong>derived from the periwinkle plant. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inhibition of tyrosine kinase activity</strong> is the<strong> mechanism of action</strong> of drugs such as<strong> imatinib</strong>, which is <strong>drug of choice</strong> for <strong>CML and GIST. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibition of DNA synthesis:</span></strong><span style=\"font-size:12.0pt\"> While some <strong>chemotherapeutic agents </strong>do <strong>inhibit DNA synthesis,</strong> the<strong> drugs derived </strong>from the <strong>periwinkle plan</strong>t<strong> do not</strong> act through this<strong> mechanism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of DNA topoisomerase II:</span></strong><span style=\"font-size:12.0pt\"> This is the <strong>mechanism of action</strong> for drugs like<strong> etoposide</strong>, not vinca alkaloids.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibition of tyrosine kinase activity:</span></strong><span style=\"font-size:12.0pt\"> Drugs like<strong> imatinib inhibit tyrosine kinase activity</strong> and are used for conditions such as <strong>chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), </strong>which is <strong>not</strong> the mechanism for <strong>vinca alkaloids.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vinca alkaloids,</strong> such as<strong> vincristine and vinblastine</strong>, work by<strong> inhibiting microtubule polymerization, </strong>leading to <strong>disruption of mitotic</strong> <strong>spindle formation,</strong> <strong>cell cycle arrest</strong>, and<strong> ultimately apoptosis</strong>. This mechanism is<strong> distinct </strong>and <strong>should no</strong>t be confused with drugs that<strong> inhibit DNA synthesis, DNA topoisomerase II,</strong> or<strong> tyrosine kinase activity.</strong></span></span></span></p>",
      "correct_choice_id": 43626,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10917,
      "choices": [
        {
          "id": 43634,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Stabilizes microtubules and prevent depolymerization</span></p>"
        },
        {
          "id": 43635,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Used in ovarian, cervix and breast cancer</span></p>"
        },
        {
          "id": 43636,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Most commonly causes myelosuppression and alopecia</span></p>"
        },
        {
          "id": 43637,
          "text": "<p><span style=\"font-size:12.0pt;\">Obtained from E. coli</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">All the following are true about paclitaxel except:</span></p>",
      "unique_key": "Q4211879",
      "question_audio": null,
      "question_video": null,
      "map_id": 36460,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D) Obtained from E. coli</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Paclitaxel </strong>is a<strong> chemotherapy </strong>drug that<strong> stabilizes microtubules </strong>and <strong>prevents their depolymerization,</strong> leading to<strong> cell</strong> <strong>cycle arrest and apoptosis.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is <strong>commonly used</strong> in the treatment of<strong> ovarian, cervical, and breast cancer</strong>, among others.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Like <strong>most cytotoxic drugs, Paclitaxel</strong> is also known to cause <strong>myelosuppression and alopecia (hair loss)</strong> as common side effects.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">However, <strong>Paclitaxel</strong> is <strong>not</strong> obtained from<strong> E. coli</strong>. It is originally derived from the <strong>bark of the Pacific yew tree,</strong> <strong>Taxus</strong> <strong>brevifolia</strong>, and is now produced<strong> synthetically or through semi-synthesis.</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A. Stabilizes microtubules and prevent polymerization:</strong> The statement is almost <strong>correct</strong> but has a <strong>crucial error. Paclitaxel</strong> <strong>actually stabilizes microtubules</strong> but <strong>prevents </strong>their <strong>depolymerization, not polymerization.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B. Used in ovarian, cervix and breast cancer:</strong> This is <strong>true.</strong> <strong>Paclitaxel</strong> is<strong> used </strong>in the treatment of these <strong>cancers</strong> due to its <strong>effectiveness in inhibiting cell division.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C. Most commonly causes myelosuppression and alopecia:</strong> Also <strong>true.</strong> These are <strong>common side effects</strong> of <strong>many</strong> <strong>chemotherapeutic agents</strong>, including<strong> paclitaxel.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Paclitaxel</strong>, a <strong>chemotherapeutic agent</strong> that is<strong> known</strong> for its <strong>ability to stabilize microtubules </strong>and thereby <strong>prevent their</strong> <strong>depolymerization</strong>, leading to <strong>inhibition of cell division</strong> in <strong>cancer treatment. </strong>It is associated with<strong> side effects</strong> such as <strong>myelosuppression and alopecia;</strong> and it was<strong> originally</strong> obtained from the <strong>bark of the Pacific yew tree</strong> and now can be <strong>produced</strong> <strong>synthetically.</strong></span></p>",
      "correct_choice_id": 43637,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10919,
      "choices": [
        {
          "id": 43642,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amifostine</span></span></span></p>"
        },
        {
          "id": 43643,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea</span></span></span></p>"
        },
        {
          "id": 43644,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5FU</span></span></span></p>"
        },
        {
          "id": 43645,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bromodeoxyuridine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which is not a radiosensitizer?</span></span></p>",
      "unique_key": "Q6952089",
      "question_audio": null,
      "question_video": null,
      "map_id": 36461,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Amifostine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Amifostine </strong>is classified as a <strong>radioprotective agent</strong> rather than a<strong> radiosensitizer.</strong> It <strong>works</strong> by <strong>protecting normal tissues</strong> from the<strong> toxic</strong> <strong>effects of radiation</strong>. <strong>Amifostine</strong> is a <strong>cytoprotective prodrug</strong> that, <strong>once activated,</strong> has <strong>free radical scavenging properties,</strong> thus <strong>protecting cells</strong> from the <strong>damaging effects of radiation therapy.</strong> It selectively <strong>accumulates in normal cells</strong> over<strong> tumor cells </strong>and, <strong>upon activation</strong>, it <strong>detoxifies reactive oxygen species</strong> and<strong> other radicals</strong> generated by <strong>radiation in normal tissues.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hydroxyurea:</span></strong><span style=\"font-size:12.0pt\"> Hydroxyurea acts as a<strong> radiosensitizer</strong> by<strong> inhibiting the enzyme ribonucleotide reductase,</strong> which leads to a <strong>depletion of deoxyribonucleotides</strong> and thereby<strong> enhances the effects of radiation on cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 5FU (5-Fluorouracil):</span></strong><span style=\"font-size:12.0pt\"> <strong>5FU </strong>is a <strong>chemotherapy agent</strong> that also functions as a <strong>radiosensitizer.</strong> It is <strong>incorporated </strong>into<strong> RNA </strong>and <strong>DNA </strong>and<strong> interfere</strong>s with the <strong>synthesis</strong> and<strong> function of nucleic acids</strong>, <strong>enhancing radiation therapy&#39;s efficacy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bromodeoxyuridine:</span></strong><span style=\"font-size:12.0pt\"> This is a <strong>thymidine analog </strong>that is<strong> incorporated into DNA </strong>during the <strong>S-phase of the cell cycle</strong>, making <strong>DNA more </strong>susceptible to<strong> damage by radiation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">key differences between radiosensitizers and radioprotectors:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-143815.png\" style=\"height:547px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 43642,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10920,
      "choices": [
        {
          "id": 43646,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin </span></span></span></p>"
        },
        {
          "id": 43647,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Minocycline </span></span></span></p>"
        },
        {
          "id": 43648,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine </span></span></span></p>"
        },
        {
          "id": 43649,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 32-year-old female presents to the clinic with a complaint of a rash on her arms and legs that has been present for the past few weeks. She reports feeling fatigued and has been experiencing intermittent fevers. The patient has a history of Hodgkin&#39;s lymphoma and underwent chemotherapy treatment approximately two months ago. Her chemotherapy regimen included daunorubicin, bleomycin, and vincristine. On physical examination, the patient is noted to have multiple erythematous, linear lesions on her arms and legs that appear to be hyperpigmented in a flagellate pattern. The remainder of her examination is unremarkable. Based on the patient&#39;s clinical history and examination, which drug is most likely responsible for her skin pigmentation?</span></span></span></p>",
      "unique_key": "Q1912153",
      "question_audio": null,
      "question_video": null,
      "map_id": 36462,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> is a <strong>chemotherapeutic agent</strong> that is known to cause a <strong>distinctive pattern of skin pigmentation</strong> called <strong>&quot;flagellate pigmentation.</strong>&quot; This pattern is characterized by<strong> linear streaks of hyperpigmentation</strong> that resemble the tracks <strong>left by a whip, or flagellum</strong>. This reaction is<strong> more </strong>commonly<strong> seen in women </strong>and can occur <strong>several weeks to months</strong> after<strong> starting therapy</strong>. The <strong>pigmentation </strong>usually<strong> resolves spontaneously,</strong> but in some cases, it can <strong>persist for several months to years after stopping the medication.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/409.jpg\" style=\"height:446px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Minocycline:</span></strong><span style=\"font-size:12.0pt\"> This is an <strong>antibiotic</strong> that can cause various types of <strong>skin hyperpigmentation</strong>, but these usually take the form of<strong> blue-gray spots or diffuse pigmentation, particularly </strong>in areas of <strong>previous inflammation or sun exposure</strong>. It is <strong>not </strong>known to cause the<strong> flagellate or whip-like streaking pattern </strong>associated <strong>with Bleomycin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> While<strong> Vincristine</strong> is a<strong> chemotherapeutic agent</strong> used in the <strong>same types of cancer </strong>as<strong> Bleomycin</strong>, its <strong>side effect</strong> profile includes<strong> neurological symptoms</strong> such as <strong>peripheral neuropathy,</strong> rather than <strong>dermatological condition</strong>s like <strong>flagellate</strong> <strong>pigmentation.</strong> The<strong> presentation </strong>of such a <strong>specific skin reaction does not</strong> align with the <strong>known adverse effects of Vincristine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> As an<strong> anthracycline chemotherapeutic</strong>, <strong>Daunorubicin</strong> can cause a<strong> variety of side effects,</strong> with the most <strong>prominent being myelosuppression.</strong> It can also<strong> lead to cardiotoxicity </strong>with <strong>long-term use</strong>. However, it is <strong>not </strong>implicated in causing the characteristic <strong>flagellate pigmentation </strong>that is <strong>seen with Bleomycin therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> can lead to <strong>flagellate pigmentation</strong>, a <strong>distinct dermatologic reaction </strong>characterized by <strong>whip-like hyperpigmented streaks</strong>. This <strong>adverse effect </strong>should be recognized by<strong> healthcare providers</strong> as a<strong> potential delayed side effect of the drug,</strong> particularly in <strong>patients with a history of cancer </strong>treatment including<strong> Bleomycin.</strong></span></span></span></p>",
      "correct_choice_id": 43646,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10922,
      "choices": [
        {
          "id": 43654,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alkylation of DNA </span></span></span></p>"
        },
        {
          "id": 43655,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crosslinking of DNA </span></span></span></p>"
        },
        {
          "id": 43656,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microtubule inhibition </span></span></span></p>"
        },
        {
          "id": 43657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proteosome inhibition</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents to the oncology clinic with a 6-month history of progressively worsening headaches and nausea. He has no significant past medical history. MRI reveals a large, heterogeneously enhancing mass in the right frontal lobe. Biopsy confirms the diagnosis of glioblastoma multiforme. The patient is started on temozolomide. What is the mechanism of action of temozolomide? </span></span></span></p>",
      "unique_key": "Q9845125",
      "question_audio": null,
      "question_video": null,
      "map_id": 36463,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Alkylation of DNA</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Temozolomide</strong> works primarily through the <strong>alkylation of DNA,</strong> where it <strong>methylates guanine residues</strong> at the<strong> O6 and N7 positions</strong>. This <strong>methylation damages the DNA, </strong>leading to <strong>errors in replication </strong>that the cancer cell<strong> cannot repair, </strong>ultimately <strong>triggering cell</strong> <strong>death</strong>. <strong>This mechanism</strong> is particularly<strong> effective</strong> against<strong> rapidly dividing cells</strong>, such as those found in<strong> glioblastoma multiform</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Crosslinking of DNA:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Crosslinking of DNA strands</strong> is characteristic of <strong>platinum-based</strong> <strong>chemotherapeutic</strong> agents such as<strong> cisplatin and carboplatin</strong>, which form <strong>covalent bonds between adjacent guanine bases, </strong>thereby <strong>preventing DNA</strong> from being <strong>unwound for replication or transcription.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Microtubule inhibition:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Microtubule inhibitors</strong> like <strong>paclitaxel and vinblastine</strong> <strong>disrupt</strong> <strong>microtubule dynamics</strong>, which are critical for<strong> cell division</strong>, particularly during<strong> mitosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Proteosome inhibition:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Proteosome inhibitors</strong>, such as <strong>bortezomib and carfilzomib,</strong> <strong>block</strong> the<strong> proteasome&#39;s </strong>role in <strong>degrading misfolded proteins</strong>, which causes an accumulation of <strong>defective proteins </strong>and<strong> induces apoptosis</strong> in <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Temozolomide&#39;s</strong> mechanism of action as a<strong> DNA alkylating agent </strong>makes it <strong>effective in treating glioblastoma multiforme </strong>by inducing <strong>lethal DNA damage</strong> in the<strong> rapidly dividing tumor cells</strong>. This action highlights the<strong> importance of DNA integrity in cell survival</strong> and the <strong>therapeutic targeting of DNA repair </strong>mechanisms in <strong>cancer treatment.</strong></span></span></span></p>",
      "correct_choice_id": 43654,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10924,
      "choices": [
        {
          "id": 43662,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mechlorethamine</span></span></span></p>"
        },
        {
          "id": 43663,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oncovin</span></span></span></p>"
        },
        {
          "id": 43664,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Procarbazine</span></span></span></p>"
        },
        {
          "id": 43665,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old male was on treatment with MOPP regimen for Hodgkin&rsquo;s lymphoma. He recently attended a party and had bouts of alcohol with his friends. Soon after, he started experiencing flushing of the face, headache, nausea, vomiting, chest pain, weakness, blurred vision, mental confusion, sweating, choking, breathing difficulty, and anxiety. These effects began about 10 minutes after drinking and lasted for 1 hour. What drug is likely to cause this presentation?</span></span></span></p>",
      "unique_key": "Q8140329",
      "question_audio": null,
      "question_video": null,
      "map_id": 36464,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Procarbazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>symptoms</strong> described are consistent with a condition called <strong>disulfiram-like reaction, </strong>which can occur when <strong>alcohol is</strong> <strong>consumed</strong> while taking <strong>certain medication</strong>s. Among the drugs used in<strong> MOPP regimen for Hodgkin&#39;s lymphoma</strong>, the most likely to<strong> cause disulfiram-like reaction with alcohol </strong>is <strong>procarbazine.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Procarbazine </strong>is an<strong> alkylating agent</strong>. It can cause a <strong>disulfiram-like reaction</strong> when <strong>alcohol is consumed, </strong>which can result in symptoms such as<strong> flushing, headache, nausea, vomiting, chest pain, weakness, blurred vision, mental confusion,</strong> s<strong>weating, choking, breathing difficulty, and anxiety</strong>. Patients should be <strong>advised to avoid alcohol</strong> while<strong> taking</strong> <strong>procarbazine to prevent this reaction.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mechlorethamine:</span></strong><span style=\"font-size:12.0pt\"> Also part of the <strong>MOPP regimen, </strong>mechlorethamine is an <strong>alkylating agent </strong>that causes <strong>DNA crosslinks</strong> but<strong> does not </strong>induce a<strong> disulfiram-like reaction with alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oncovin (Vincristine):</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a <strong>chemotherapeutic agent</strong> that<strong> inhibits microtubule formation</strong>. It <strong>does not</strong> interact with<strong> alcohol </strong>to produce <strong>disulfiram-like reactions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> A<strong> corticosteroid</strong> used in various <strong>chemotherapy regimens,</strong> including<strong> MOPP, prednisone </strong>has many effects on <strong>metabolism and the immune system</strong> but <strong>does not</strong> cause<strong> disulfiram-like reactions </strong>when combined with <strong>alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Procarbazine</strong> can induce a <strong>disulfiram-like reaction</strong> when<strong> taken</strong> with <strong>alcohol,</strong> manifesting as<strong> severe and acute symptoms </strong>shortly after alcohol consumption. It is <strong>crucial for patients</strong> receiving <strong>procarbazine</strong> to <strong>avoid alcohol to prevent</strong> these potentially <strong>distressing</strong> <strong>and dangerous effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Drugs causing disulfiram like reaction:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-145325.png\" style=\"height:554px; width:800px\" /></span></strong></span></span></p>",
      "correct_choice_id": 43664,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10926,
      "choices": [
        {
          "id": 43670,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitomycin C</span></span></span></p>"
        },
        {
          "id": 43671,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea</span></span></span></p>"
        },
        {
          "id": 43672,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
        },
        {
          "id": 43673,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary fibrosis is an adverse effect of which of the following anti-cancer drugs?</span></span></span></p>",
      "unique_key": "Q6810895",
      "question_audio": null,
      "question_video": null,
      "map_id": 36465,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> used in the<strong> treatment of</strong> several types of cancer, including <strong>Hodgkin&#39;s lymphoma, testicular cancer, and ovarian cancer, </strong>is <strong>well-known</strong> for<strong> its potential </strong>to cause<strong> pulmonary fibrosis</strong>.<strong> Pulmonary toxicity </strong>is a<strong> major limiting factor</strong> in its usage.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mechanism by which <strong>bleomycin causes lung injury</strong> is thought to involve its ability to <strong>induce DNA strand breaks </strong>and <strong>free radical</strong> <strong>formation, leading to inflammation and fibrotic changes in the lungs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Mitomycin C</strong>: This is an <strong>alkylating agent</strong> used in <strong>cancer chemotherapy.</strong> Its common <strong>side effects</strong> include <strong>bone marrow</strong> <strong>suppression, nausea, vomiting, and renal toxicity,</strong> but it is <strong>not</strong> primarily known for <strong>causing pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Hydroxyurea</strong>: This medication is <strong>used for</strong> various <strong>myeloproliferative disorders</strong> and <strong>sickle cell disease.</strong> Its <strong>side effects </strong>often include <strong>bone marrow suppression and gastrointestinal symptoms,</strong> but it is<strong> not</strong> typically associated with <strong>pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cisplatin</strong>: A <strong>platinum-containing chemotherapy </strong>drug<strong> used to</strong> treat various <strong>types of cancers.</strong> While<strong> nephrotoxicity (kidney</strong> <strong>damage) and ototoxicity (hearing damage)</strong> are common adverse effects, it is <strong>not</strong> typically associated with <strong>pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Bleomycin</span></strong><span style=\"font-size:12.0pt\"> is known to cause <strong>pulmonary fibrosis</strong>, which is a condition characterized by the<strong> scarring and thickening of lung tissue.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/05/whatsapp-image-2024-02-05-at-180437_nS2gu6G.jpeg\" style=\"height:702px; width:491px\" /></span></p>",
      "correct_choice_id": 43672,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10928,
      "choices": [
        {
          "id": 43678,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
        },
        {
          "id": 43679,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carboplatin</span></span></span></p>"
        },
        {
          "id": 43680,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxaliplatin</span></span></span></p>"
        },
        {
          "id": 43681,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the platinum compounds</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharyngolaryngeal dysesthesia is a peculiar side effect of which of the following drugs? </span></span></span></p>",
      "unique_key": "Q9627413",
      "question_audio": null,
      "question_video": null,
      "map_id": 36466,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Oxaliplatin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Oxaliplatin</span></strong><span style=\"font-size:12.0pt\"> is known to cause <strong>pharyngolaryngeal dysesthesia, </strong>which is an <strong>unusual sensory side effect.</strong> Patients can experience<strong> acute</strong> <strong>sensations of cold or burning in the throat and laryngeal area.</strong> This often o<strong>ccurs soon after treatment </strong>and can be<strong> triggered by</strong> <strong>exposure to cold temperatures or the consumption of cold foods and drinks.</strong> While this effect is typically<strong> reversible and resolves</strong> a<strong>fter the drug is discontinued,</strong> it can be <strong>quite distressing for patients during treatmen</strong>t.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> While Cisplatin is associated with various <strong>side effects,</strong> including <strong>nephrotoxicity and ototoxicity,</strong> <strong>pharyngolaryngeal dysesthesia </strong>is<strong> not</strong> commonly<strong> seen </strong>with this <strong>medication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carboplatin:</span></strong><span style=\"font-size:12.0pt\"> Carboplatin, <strong>another platinum-based chemotherapeutic agent</strong>, tends to have a<strong> different side effect profile</strong>, and<strong> pharyngolaryngeal dysesthesia </strong>is<strong> not</strong> a characteristic <strong>side effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. All the platinum compounds:</span></strong><span style=\"font-size:12.0pt\"> This option is too broad. While<strong> all platinum compounds </strong>have<strong> side effects r</strong>elated to their <strong>cytotoxicity, pharyngolaryngeal dysesthesia </strong>is specific to <strong>Oxaliplatin </strong>and is <strong>not</strong> generally <strong>seen </strong>with <strong>other platinum-based</strong> <strong>chemotherapeutic agents.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>patients receiving chemotherapy </strong>with <strong>Oxaliplatin </strong>report <strong>unusual sensations in the throat and laryngeal area</strong>, especially in <strong>response to cold,</strong> it is likely<strong> due to pharyngolaryngeal dysesthesia</strong>. It&#39;s important for<strong> clinicians to be aware of this potential side</strong> <strong>effect </strong>and to<strong> counsel patients </strong>appropriately to<strong> manage symptoms</strong> and<strong> improve their quality of life during treatment.</strong></span></span></span></p>",
      "correct_choice_id": 43680,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10929,
      "choices": [
        {
          "id": 43682,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
        },
        {
          "id": 43683,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 Mercaptopurine</span></span></span></p>"
        },
        {
          "id": 43684,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 Thioguanine</span></span></span></p>"
        },
        {
          "id": 43685,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Capacitabine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dose of which of the following drugs should be reduced when prescribed along with allopurinol?&nbsp;</span></span></span></p>",
      "unique_key": "Q8034663",
      "question_audio": null,
      "question_video": null,
      "map_id": 36467,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 6 mercaptopurine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">6-Mercaptopurine (6-MP):</span></strong><span style=\"font-size:12.0pt\"> <strong>Allopurinol</strong> is a<strong> xanthine oxidase inhibitor </strong>used to<strong> decrease the production of uric acid.</strong> Because <strong>xanthine oxidase</strong> is also involved in the<strong> catabolism of 6-MP,</strong> <strong>co-administration with allopurinol</strong> leads to <strong>increased levels of 6-MP.</strong> This can result in <strong>excessive myelosuppression</strong>. Therefore, when<strong> allopurinol is administered concurrently with 6-MP, </strong>the <strong>dose of 6-MP</strong> must be<strong> reduced (commonly to one-third or one-fourth of its standard dose) </strong>to <strong>prevent</strong> potentially <strong>life-threatening toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> While methotrexate is <strong>metabolized by the liver</strong> and <strong>excreted by the kidneys, </strong>a<strong>llopurinol</strong> <strong>does not</strong> significantly affect<strong> its plasma levels.</strong> However, <strong>close monitoring</strong> is still warranted due to the<strong> potential for increased toxicity,</strong> but <strong>specific dose reduction </strong>due to<strong> allopurinol</strong> is <strong>not a standard practice.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 6-Thioguanine:</span></strong><span style=\"font-size:12.0pt\"> Like<strong> 6-MP, 6-thioguanine is a purine analog</strong>, and though it has a <strong>similar mechanism of action</strong>, the effect of <strong>allopurinol</strong> on<strong> its metabolism</strong> <strong>does not</strong> usually require a<strong> dose adjustment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Capecitabine:</span></strong><span style=\"font-size:12.0pt\"> Capecitabine, an <strong>oral prodrug</strong> that is<strong> metabolized into 5-fluorouracil,</strong> is <strong>not</strong> primarily <strong>affected</strong> by <strong>allopurinol,</strong> and <strong>dose adjustments</strong> are typically<strong> not </strong>necessary when these<strong> drug</strong>s are<strong> used concurrently.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>prescribing 6-Mercaptopurine</strong> in<strong> conjunction with allopurinol, </strong>it&#39;s essential to <strong>reduce the dosage of 6-MP to prevent</strong> <strong>increased drug levels </strong>and<strong> potential toxicity </strong>due to the<strong> inhibition of xanthine oxidase by allopurinol. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This<strong> drug interaction</strong> <strong>underscores </strong>the importance of understanding the <strong>metabolic pathways of chemotherapeutic agents</strong> and the <strong>impact of concomitant medications</strong> on these pathways.</span></span></span></p>",
      "correct_choice_id": 43683,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10930,
      "choices": [
        {
          "id": 43686,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
        },
        {
          "id": 43687,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
        },
        {
          "id": 43688,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine</span></span></span></p>"
        },
        {
          "id": 43689,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dacarbazine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient is being treated with ABVD chemotherapy for Hodgkin lymphoma. He presents for cycle 4 of a planned 6 cycles with a new-onset cough. He states it started a week ago and he also feels like he has a little trouble catching his breath. Which drug in the ABVD regimen is the most likely cause of his pulmonary toxicity?</span></span></span></p>",
      "unique_key": "Q3479799",
      "question_audio": null,
      "question_video": null,
      "map_id": 36468,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> ABVD regimen,</strong> used in the treatment of<strong> Hodgkin lymphoma, </strong>includes four drugs: <strong>Doxorubicin, Bleomycin, Vinblastine, </strong>and <strong>Dacarbazine</strong>. Each of these drugs has <strong>its own side effect profile.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the given <strong>patient</strong> who <strong>presents with </strong>a<strong> new-onset cough and shortness of breath,</strong> the drug most likely responsible for these symptoms of <strong>pulmonary toxicity is&nbsp;bleomycin</strong>. The pulmonary toxicity can be manifested as <strong>interstitial pneumonitis and pulmonary</strong> <strong>fibrosis.</strong> Symptoms like<strong> coughing and difficulty breathing</strong> are characteristic of <strong>bleomycin-induced lung damage</strong>. The <strong>risk of</strong> <strong>pulmonary toxicity</strong> <strong>increases </strong>with <strong>higher cumulative doses.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Doxorubicin</strong>: <strong>As part </strong>of the <strong>ABVD regimen,</strong> <strong>doxorubicin&#39;s</strong> primary toxicities are <strong>cardiotoxicity and myelosuppression</strong>. <strong>Pulmonary toxicity</strong> is<strong> not</strong> a common side effect of <strong>doxorubicin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Vinblastine</strong>: <strong>Another component</strong> of the <strong>ABVD regimen</strong>, vinblastine typically causes side effects such as <strong>neurotoxicity and</strong> <strong>myelosuppression. </strong>It is<strong> not </strong>generally associated with<strong> pulmonary toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Dacarbazine</strong>: The<strong> final drug</strong> in the <strong>ABVD regimen</strong>, <strong>dacarbazine</strong> can cause <strong>nausea, vomiting, and myelosuppression,</strong> but like the others, it is<strong> not</strong> known for<strong> causing pulmonary toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In <strong>patients</strong> <strong>undergoing ABVD chemotherapy</strong> who develop <strong>respiratory symptoms </strong>such as <strong>coughing and shortness of breath,</strong> <strong>Bleomycin </strong>is the<strong> agent</strong> within the regimen <strong>most likely</strong> to be <strong>responsible for pulmonary toxicity.</strong></span></span></span></p>",
      "correct_choice_id": 43687,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10931,
      "choices": [
        {
          "id": 43690,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV hydration, mesna, and frequent urinalyses</span></span></span></p>"
        },
        {
          "id": 43691,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leucovorin and frequent urinalyses</span></span></span></p>"
        },
        {
          "id": 43692,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allopurinol and frequent urinalyses</span></span></span></p>"
        },
        {
          "id": 43693,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV hydration, prophylactic antibiotics, and frequent urinalyses</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 64-year-old male about to undergo therapy for Rhabdomyosarcoma. His chemotherapy includes vincristine, dactinomycin, cyclophosphamide, doxorubicin and ifosfamide. Which of the following is most appropriate to include in chemotherapy orders for this patient? </span></span></span></p>",
      "unique_key": "Q3920056",
      "question_audio": null,
      "question_video": null,
      "map_id": 36469,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) IV hydration, mesna, and frequent urinalyses.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>chemotherapy drugs</strong> listed <strong>(vincristine, dactinomycin, cyclophosphamide, doxorubicin, and ifosfamide)</strong> can be associated with <strong>potential toxicities</strong>, including<strong> damage to the bladder and kidneys</strong>. Therefore, it is important to include <strong>measures to protect </strong>these <strong>organs </strong>during<strong> treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>IV hydration, mesna, and frequent urinalyses,</strong> which are <strong>commonly used to protect the bladder and kidneys</strong> during <strong>chemotherapy</strong> with <strong>ifosfamide and cyclophosphamide. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>IV hydration</strong> can help <strong>flush out</strong> the drugs and prevent the<strong> buildup of toxic metabolites </strong>in the <strong>kidneys. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Mesna</strong> can <strong>prevent damage to the bladder lining </strong>by <strong>neutralizing metabolites of ifosfamide. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Frequent urinalyses</strong> can<strong> help</strong> <strong>monitor </strong>for <strong>signs of kidney or bladder toxicity.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Leucovorin and frequent urinalyses. </span></strong><span style=\"font-size:12.0pt\"><strong>Leucovorin</strong> is used in <strong>combination with the methotrexate,</strong> which is<strong> not </strong>included in the <strong>listed chemotherapy drugs. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Allopurinol and frequent urinalyses</span></strong><span style=\"font-size:12.0pt\">. <strong>Allopurinol </strong>is used to<strong> prevent uric acid buildup </strong>during <strong>chemotherapy for lymphoma</strong> but is<strong> not</strong> used for <strong>rhabdomyosarcoma. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IV hydration, prophylactic antibiotics, and frequent urinalyses</span></strong><span style=\"font-size:12.0pt\">. <strong>Prophylactic antibiotics </strong>may be used to <strong>prevent infections</strong> <strong>during chemotherapy</strong>, but is <strong>not</strong> typically <strong>required for rhabdomyosarcoma chemotherapy. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For<strong> patients receiving chemotherapy regimens</strong> that include <strong>cyclophosphamide and ifosfamide,</strong> it is crucial to <strong>implement measures</strong> to<strong> prevent bladder toxicity. </strong>This includes the <strong>use of IV hydration to facilitate dilution of urine, mesna to chemically neutralize toxic</strong> <strong>metabolites,</strong> and <strong>regular monitoring of urinary function</strong> through<strong> frequent urinalyses</strong>. These <strong>steps </strong>are<strong> essential to protect </strong>the <strong>patient&rsquo;s urinary tract </strong>and ensure the<strong> safe administration of potentially nephrotoxic chemotherapy agents.</strong></span></span></span></p>",
      "correct_choice_id": 43690,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10932,
      "choices": [
        {
          "id": 43694,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G1 phase</span></span></span></p>"
        },
        {
          "id": 43695,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S phase</span></span></span></p>"
        },
        {
          "id": 43696,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G2 phase</span></span></span></p>"
        },
        {
          "id": 43697,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">M phase</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine inhibits which phase of cell cycle? </span></span></span></p>",
      "unique_key": "Q8041542",
      "question_audio": null,
      "question_video": null,
      "map_id": 36470,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) M phase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Vinblastine</span></strong><span style=\"font-size:12.0pt\"> is a <strong>chemotherapeutic agent</strong> classified under the<strong> vinca alkaloids,</strong> which are known for their<strong> ability to inhibit microtubule</strong> <strong>formation.</strong> This action<strong> disrupts the mitotic spindle formation</strong> necessary for <strong>chromosome separation</strong> during the <strong>M</strong> <strong>phase (mitosis) of the cell cycle</strong>. Therefore, <strong>vinblastine effectively halts</strong> the <strong>cell cycle in the M phase, preventing cells</strong> <strong>from properly</strong> <strong>completing mitosis</strong>,<strong> leading to cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This phase involves the<strong> preparation of the cell to enter the S phase </strong>but is<strong> not </strong>affected by <strong>vinblastine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> The phase where <strong>DNA replication occurs</strong>; <strong>vinblastine does not</strong> directly affect <strong>DNA synthesis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. G2 phase:</span></strong><span style=\"font-size:12.0pt\"> The phase where the <strong>cell prepares for mitosis</strong>; although important for <strong>cell cycle progression,</strong> <strong>vinblastine</strong> specifically<strong> targets and disrupts</strong> the<strong> mitotic phase rather </strong>than <strong>this preparatory phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-153051.png\" style=\"height:408px; width:1000px\" /></span></u></strong></span></span></p>",
      "correct_choice_id": 43697,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10934,
      "choices": [
        {
          "id": 43702,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Actinomycin D </span></span></span></p>"
        },
        {
          "id": 43703,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asparaginase</span></span></span></p>"
        },
        {
          "id": 43704,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitomycin </span></span></span></p>"
        },
        {
          "id": 43705,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6-mercaptopurine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is an inhibitor of DNA replication? </span></span></span></p>",
      "unique_key": "Q7537451",
      "question_audio": null,
      "question_video": null,
      "map_id": 36472,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 6-mercaptopurine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">6-mercaptopurine (6-MP):</span></strong><span style=\"font-size:12.0pt\"> This drug is a <strong>purine antimetabolite</strong> that<strong> interferes with DNA replication.</strong> It is<strong> incorporated</strong> into <strong>DNA</strong> <strong>during synthesis</strong>, leading to <strong>faulty DNA and inhibition of replication.</strong> <strong>6-MP</strong> is particularly used in the treatment of<strong> leukemia because</strong> the<strong> malignant cells </strong>have a <strong>high turnover rate</strong> and are<strong> more likely to incorporate</strong> these <strong>false building blocks</strong> into <strong>their DNA.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Actinomycin D:</span></strong><span style=\"font-size:12.0pt\"> This drug <strong>binds </strong>to <strong>DNA and inhibits RNA polymerase, </strong>which is responsible for <strong>transcribing RNA from the</strong> <strong>DNA template.</strong> While it does <strong>affect genetic material,</strong> it is <strong>not</strong> a <strong>direct inhibitor of DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Asparaginase:</span></strong><span style=\"font-size:12.0pt\"><strong> Works</strong> by <strong>breaking down</strong> the <strong>amino acid asparagine</strong>, which is necessary for<strong> protein synthesis in tumor cells.</strong> It <strong>does no</strong>t directly <strong>inhibit DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mitomycin:</span></strong><span style=\"font-size:12.0pt\"> Acts as an <strong>alkylating agent</strong>, forming <strong>cross-links</strong> within the <strong>DNA strands</strong>. Although this <strong>affects DNA structure</strong> and<strong> function</strong>, it <strong>does not</strong> <strong>inhibit</strong> the<strong> replication process directly like 6-MP does.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>6-mercaptopurine</strong> is a <strong>crucial medication</strong> in the treatment of certain types of<strong> leukemia,</strong> where it <strong>serves as an inhibitor of DNA</strong> <strong>replication </strong>by<strong> mimicking purine nucleotides.</strong> This specific action <strong>disrupts the synthesis of DNA</strong>, which is <strong>critical for the proliferation</strong> of<strong> cancer cells. </strong></span></span></span></p>",
      "correct_choice_id": 43705,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10935,
      "choices": [
        {
          "id": 43706,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Etoposide </span></span></span></p>"
        },
        {
          "id": 43707,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 43708,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel </span></span></span></p>"
        },
        {
          "id": 43709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neurotoxicity is dose-limiting for which of the following drugs? </span></span></span></p>",
      "unique_key": "Q5939436",
      "question_audio": null,
      "question_video": null,
      "map_id": 36473,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Vincristine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine</strong> can <strong>damage</strong> <strong>peripheral nerves,</strong> leading to a range of <strong>neurological symptoms</strong> such as <strong>numbness, tingling, weakness, and</strong> <strong>difficulty walking</strong>. The<strong> severity of neurotoxicity </strong>is directly related to the <strong>dose of the drug</strong>, and it is a <strong>dose-limiting toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Etoposide:</span></strong><span style=\"font-size:12.0pt\"> Etoposide can cause<strong> myelosuppression</strong>, leading to<strong> low blood cell counts,</strong> which is generally the<strong> dose-limiting</strong> <strong>toxicity </strong>for this drug.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> While methotrexate can cause various<strong> side effects</strong> including<strong> mucositis and hepatotoxicity,</strong> its <strong>dose-limiting</strong> <strong>toxicity </strong>is often <strong>myelosuppression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Paclitaxel:</span></strong><span style=\"font-size:12.0pt\"> Paclitaxel can cause <strong>myelosuppression and neuropathy</strong>, but the <strong>primary dose-limiting toxicity </strong>is typically <strong>bone</strong> <strong>marrow suppression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine&#39;s dose-limiting toxicity</strong> is<strong> neurotoxicity,</strong> which necessitates careful <strong>monitoring of neurological symptoms</strong> and <strong>adjustment</strong> of <strong>dosing </strong>to<strong> prevent severe peripheral neuropathy. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Myelosuppression </strong>is <strong>dose limiting </strong>for<strong> paclitaxel, etoposide, and methotrexate.</strong></span></span></span></p>",
      "correct_choice_id": 43709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10937,
      "choices": [
        {
          "id": 43714,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of Dihydrofolate reductase </span></span></span></p>"
        },
        {
          "id": 43715,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of N5 tetrahydro folate reductase </span></span></span></p>"
        },
        {
          "id": 43716,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of tyrosine kinase</span></span></span></p>"
        },
        {
          "id": 43717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of purine metabolism</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 20-year-old boy presented with slow growing mass on the medial side of thigh. Investigations revealed it to be osteosarcoma and patient was started on methotrexate. Mechanism of action of methotrexate as an anticancer drug is:</span></span></span></p>",
      "unique_key": "Q6098509",
      "question_audio": null,
      "question_video": null,
      "map_id": 36474,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Inhibition of Dihydrofolate reductase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is an <strong>antimetabolite</strong> that interferes with the<strong> synthesis of nucleic acids </strong>in <strong>rapidly dividing cells</strong> such as <strong>cancer cells.</strong> It <strong>inhibits the activity of DHFR</strong>, which is an enzyme that is necessary for the <strong>synthesis of tetrahydrofolate, </strong>a <strong>coenzyme</strong> that is involved in the <strong>synthesis of nucleotides</strong>. By<strong> inhibiting DHFR, methotrexate reduces the availability of tetrahydrofolate,</strong> which in turn<strong> inhibits</strong> the<strong> synthesis of nucleotides</strong>, ultimately leading to <strong>decreased DNA synthesis and cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibition of N5 tetrahydro folate reductase:</span></strong><span style=\"font-size:12.0pt\"> This option is<strong> incorrect </strong>because there is<strong> no enzyme</strong> named <strong>N5 tetrahydro</strong> <strong>folate reductase</strong> that<strong> methotrexate</strong> is known to <strong>inhibit.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of tyrosine kinase:</span></strong><span style=\"font-size:12.0pt\"> This is the <strong>action of </strong>drugs like <strong>imatinib,</strong> <strong>not methotrexate. Tyrosine kinase inhibitors</strong> are <strong>used</strong> in the treatment of certain <strong>types of leukemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibition of purine metabolism:</span></strong><span style=\"font-size:12.0pt\"> While <strong>methotrexate</strong> can <strong>impact purine metabolism indirectly </strong>by <strong>its action</strong> on <strong>DHFR</strong>, the <strong>direct inhibition of purine metabolism </strong>is characteristic of drugs like <strong>6-mercaptopurine, not methotrexate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key <strong>mechanism of action</strong> of<strong> methotrexate</strong> in the treatment of <strong>cancer</strong>, including <strong>osteosarcoma,</strong> is the<strong> inhibition of dihydrofolate</strong> <strong>reductase.</strong> This action results in <strong>decreased nucleotide biosynthesis</strong>, which is<strong> vital for DNA replication </strong>and <strong>cell division in rapidly</strong> <strong>dividing cancer cells. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding this <strong>mechanism</strong> is critical when <strong>using methotrexate</strong> as an <strong>anticancer agent</strong>, as it informs<strong> both its therapeutic effects</strong> <strong>and its toxicity profile.</strong></span></span></span></p>",
      "correct_choice_id": 43714,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}